# FOX Biosystems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fox-biosystems

- Industry: Medical Devices & Equipment
- Headquarters: Limburg, Belgium
- Website: www.foxbiosystems.com/
- Total disclosed funding: $3M
- Latest round: Series B (Sep 12, 2022)
- Investors on record: 4

## About

Based in Limburg, Belgium, and founded in 2016, FOX Biosystems provides innovative fiber-optic-based surface plasmon resonance (FO-SPR) biosensor technology. As of 2023, the company is headed by its CEO Mark Truesdale. In January 2023, the firm raised EUR 5.8 million in Series A funding from investor HERAN Partners, LRM, K.U. Leuven Research & Development, The Gemma Frisius Fund and Netscientific.

The company offers real-time, label-free analysis instruments based on an innovative fiber-optic-based surface plasmon resonance biosensor technology that enables users to generate high-quality biomolecular data such as affinity data, kinetic data, and concentration measurements. The firm product range includes White Fox, Probes, Fo-SPR, and many more.

The company plans to use the January 2023 funding to further develop its technology and bring it to more customers worldwide.

## Funding rounds

- Series B, Sep 12, 2022, $3M — K.U. Leuven Research & Development, LRM, HERAN Partners, Netscientific

## Investors

- K.U. Leuven Research & Development (https://capitalatlas.ai/funds/k-u-leuven-research-development) — Series B
- LRM (https://capitalatlas.ai/funds/lrm) — Series B
- HERAN Partners (https://capitalatlas.ai/funds/heran-partners) — Series B
- Netscientific — Series B